- Home
- STTK
STTK
Shattuck Labs Inc.
as 07-26-2024 4:00pm EST
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 175.0M | IPO Year: | 2020 |
| Target Price: | $15.00 | AVG Volume (30 days): | 658.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $11.76 | Next Earning Date: | 08-08-2024 |
| Revenue: | $2,715,000 | Revenue Growth: | 282.93% |
| Revenue Growth (this year): | 48.88% | Revenue Growth (next year): | 9.57% |
Stock Insider Trading Activity of Shattuck Labs Inc. (STTK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schreiber Taylor | STTK | Chief Executive Officer | Jun 26 '24 | Buy | $3.47 | 14,400 | $50,011.20 | 34,502 | SEC Form 4 |
| Stout Stephen | STTK | See Remarks | Mar 6 '24 | Sell | $10.53 | 4,895 | $51,544.35 | 74,437 | SEC Form 4 |
| Stout Stephen | STTK | See Remarks | Mar 6 '24 | Sell | $10.53 | 6,459 | $68,013.27 | 79,332 | SEC Form 4 |
| Stout Stephen | STTK | See Remarks | Mar 6 '24 | Sell | $10.53 | 4,650 | $48,964.50 | 79,332 | SEC Form 4 |
| Neill Andrew R | STTK | Chief Financial Officer | Jan 10 '24 | Sell | $10.00 | 25,000 | $250,000.00 | 173,446 | SEC Form 4 |
Latest Shattuck Labs Inc. News
STTK Breaking Stock News: Dive into STTK Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Zacks
17 days ago
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
MT Newswires
25 days ago
Shattuck Labs Added to Russell 2000, Russell 3000 Indexes
GlobeNewswire
a month ago
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/27/2024
Insider Monkey
a month ago
Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK)
MT Newswires
a month ago
--BTIG Downgrades Shattuck Labs to Neutral From Buy
Zacks
a month ago
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Compare STTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.